Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 11/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CTSA | P10619 | 3/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3785787 | 0.79 | PDE4B (0.65) | PDE4BKDM4ENPSR1CTSAPDE4D | |
| SCHEMBL8062503 | 0.79 | PDE4B (0.65) | PDE4BKDM4ENPSR1CTSAPDE4D | |
| SCHEMBL3785828 | 0.74 | PDE4B (0.72) | PDE4BNPSR1CTSAPDE4D | |
| SCHEMBL3785840 | 0.73 | PDE4B (0.59) | PDE4BKDM4ENPSR1CTSAMAPT | |
| SCHEMBL8507241 | 0.70 | CYP19A1 (0.60) | KDM4EALOX15CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL16046728 | 0.67 | PDE4B (0.49) | PDE4BALOX15CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3804232 | 0.67 | CYP19A1 (0.46) | PDE4B | |
| SCHEMBL3805932 | 0.65 | PDE4B (0.58) | PDE4BKDM4E | |
| SCHEMBL306570 | 0.65 | CYP19A1 (0.48) | PDE4BPDE4DMAPT | |
| SCHEMBL2401854 | 0.65 | CYP19A1 (0.71) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140301999-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2014-10-09 | — | — | US | disclosed |
| US-20140301999-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2014-10-09 | — | — | US | disclosed |
| US-20140301999-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2014-10-09 | — | — | US | disclosed |
| US-8791267-B2 | Biaryl PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders | DECODE GENETICS EHF (IS) | 2014-07-29 | — | — | US | disclosed |
| US-8791267-B2 | Biaryl PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders | DECODE GENETICS EHF (IS) | 2014-07-29 | — | — | US | disclosed |
| US-8791267-B2 | Biaryl PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders | DECODE GENETICS EHF (IS) | 2014-07-29 | — | — | US | disclosed |
| US-20120183522-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2012-07-19 | — | — | US | disclosed |
| US-20120183522-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2012-07-19 | — | — | US | disclosed |
| US-20120183522-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2012-07-19 | — | — | US | disclosed |
| US-20090324569-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2009-12-31 | — | — | US | disclosed |
| US-20090324569-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2009-12-31 | — | — | US | disclosed |
| US-20090324569-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120183522-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | PDE4A, PDE4B, PDE3B | PDE4B 2/4885KDM4E 487/4885ALOX15 1190/4885 |
| US-20140301999-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | PDE4A, PDE4B, PDE3B | PDE4B 2/4885KDM4E 487/4885ALOX15 1190/4885 |
| US-20090324569-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | PDE4A, PDE4B, PDE3B | PDE4B 2/4885KDM4E 487/4885ALOX15 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.